Indeed, there are several ongoing clinical trials using AKT inhibitors, such as capivasertib, ipatasertib and M2698 as monotherapy/in combination with other drugs in advanced solid tumors, afuresertib and perifosine as monotherapy/in combination with other agents in advanced solid tumors and in combination only in hematological malignancies, and MK-2206 as monotherapy/in combination in advanced solid tumors and hematological malignancies, and TAS-117 as monotherapy in advanced solid tumors. Here, AKT1 is linked to hematologic disorder.